Indivior Pharmaceuticals, Inc.

INDV · Nasdaq · ·

비교

US$28.15+2.6%11월 2일 종가

2026년 9월 30일까지의 수치 (2026년 10월 29일 제출 10-Q 기준)

1M: +6.2%
3M: -7.0%

Indivior Pharmaceuticals, Inc. (INDV) 주식 — 좋은 사업일까? — InspectStocks

Indivior Pharmaceuticals, Inc.

INDV · Nasdaq · ·

비교

US$28.15+2.6%11월 2일 종가

2026년 9월 30일까지의 수치 (2026년 10월 29일 제출 10-Q 기준)

1M: +6.2%
3M: -7.0%

Just reported

Q3 2026 results

From Indivior Pharmaceuticals's results release of 2026년 10월 29일; its quarterly report has since been filed.

Revenue
Actual
US$356M
+13% y/y
+3.8% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$1.12
+239% y/y
+14% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$180M
+319% y/y
+13% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$1.295B – US$1.365B+7.3% y/y Raised +6.4%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Indivior Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Drug Manufacturers Specialty and Generic

Graded A or B and worth $2B or more: A first, then the largest.

All 78 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

어떻게 돈을 버는가

SUBLOCADE monthly buprenorphine injections74%
Sublingual buprenorphine medicines25%

매출 비중은 six months ended June 30, 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가4

SUBLOCADE
An extended-release buprenorphine injection given under the skin once a month by a health care professional to treat OUD.
SUBOXONE Film
A film containing buprenorphine and naloxone that dissolves under the tongue or against the inside of the cheek to treat OUD.
SUBUTEX Tablet
A buprenorphine tablet that dissolves under the tongue to treat OUD; sold mainly in Australia, France and Germany.
SUBOXONE Tablet
A buprenorphine-and-naloxone tablet for OUD that Indivior continues to sell on a limited transition basis in some countries.

누가 사는가4

Pharmaceutical wholesalers buy medicines from Indivior and distribute them to pharmacies, hospitals and other health care customers; its three largest customers together accounted for 51% of global net revenue (2025, high).
Specialty pharmacies and distributors handle medicines that require controlled storage or delivery, including SUBLOCADE.
Hospitals, addiction treatment centers and other organized health systems purchase or arrange access to medicines for patients receiving care.
Government and private health insurers reimburse for treatment, while health care professionals prescribe or administer the medicines.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1SUBLOCADE accounted for 74% of net revenue (six months ended June 30, 2026, high), making sales dependent on that product.
2The United States accounted for 85% of net revenue (2025, high).
3Indivior makes the buprenorphine active ingredient at its Hull, United Kingdom plant, but relies on Curia to manufacture SUBLOCADE.
4Aquestive is the exclusive global manufacturer and primary packager of SUBOXONE Film.
5The three largest U.S. wholesale customers accounted for 51% of global net revenue (2025, high).

잘못될 수 있는 일

1Sales depend heavily on SUBLOCADE; competing long-acting buprenorphine medicines and generic competition for other products could reduce sales or put pressure on prices.
2Reliance on outside manufacturers and packagers creates a risk that production or regulatory problems could interrupt supply; buprenorphine supply also depends on controlled-substance import and distribution rules.
3Changes to insurance coverage, government reimbursement or rules for controlled medicines could limit patient access or reduce what Indivior receives for its medicines.

전체 재무제표 보기 →

Indivior Pharmaceuticals, Inc. 소개

Indivior makes prescription medicines for opioid use disorder (OUD), a condition involving harmful opioid use. Its main product, SUBLOCADE, is a monthly injection given by a health care professional; other medicines dissolve under the tongue or inside the cheek. The company sells mainly in the United States, with sales also in Canada, Australia, France and Germany.

본사: Richmond, Virginia, United States
설립: 2014
상장 시장: Nasdaq
회계연도 종료: December 31

Indivior Pharmaceuticals, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Just reported